Hong Kong Stock Movement | Alebund Pharmaceuticals-B (09637.HK) rose nearly 4% intraday, with an amplitude of 13.53%. The Hong Kong innovative drug sector strengthened collectively. AP308, a new drug for the treatment of IgA nephropathy, received clinical trial approval from the U.S. FDA.
Zhito Finance APP has learned that Alebund Pharmaceuticals-B (09637.HK) dipped to a low today before staging a strong rebound, rising nearly 4% at its peak to HK$19.41, with a turnover of HK$17.8807 million and an amplitude of 13.53%.
Latest
